Short Summary
Tesla has filed an IPR petition challenging all 17 claims of Charge Fusion’s electric‑vehicle charging patent, arguing they are obvious over existing EV charging systems and GUIs.
Detailed Summary
In Petition IPR2025-00152, Tesla, Inc. seeks inter partes review of U.S. Patent No. 11,990,788 owned by Charge Fusion Technologies, LLC. The petition alleges that the patent’s 17 claims—covering an electrical charging system with a GUI, charge indicator, scheduling algorithm, and wireless charging features—are obvious in view of prior art references such as Sutardja, Donnelly, Letendre, Seelig, and Knockeart. Tesla emphasizes that these references were not cited during prosecution and that the claimed GUI elements constitute printed matter lacking patentable weight. The petition requests the PTAB to institute the review and invalidate the claims, while arguing against discretionary denial under §§ 325(d) and 314(a).
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Tesla, Inc. vs Charge Fusion Technologies, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Microsoft CorporationvsDialect, LLC
Microsoft and Dialect have jointly moved to keep their settlement agreement confidential, invoking statutory provisions for business‑confidential information.
REVELYST SALES LLC et al.vsBrainGuard Technologies Inc.
Revelyst Sales LLC has filed an IPR petition seeking cancellation of 13 claims of BrainGuard’s helmet safety patent, alleging anticipation and obviousness over multiple prior‑art helmets. The petition details claim‑by‑claim comparisons to Weber, Von Holst, Kleiven, Madey, Piper and Halldin references.
Medtronic, Inc.vsMoskowitz Family LLC
The PTAB granted institution for IPR2025-01598, allowing Medtronic to challenge Moskowitz Family LLC's patent 9005293 at the merits stage.
Bicara Therapeutics, Inc.vsThe John Hopkins University et al.
Bicara Therapeutics has filed a PTAB Post‑Grant Review petition seeking cancellation of all nine claims of Johns Hopkins' 2025 antibody‑fusion protein patent, alleging lack of written description, lack of enablement, and improper claim dependency.
SAMSUNG ELECTRONICS CO., LTD. et al.vsiCashe, Inc.
The Director denied Samsung's petitions for review of the PTAB's decisions not to institute several IPRs against iCashe's patents. The order affirms the PTAB's original institution denials.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.